Xintela reports positive preclinical results in cancer project

Read in PDF

Lund, Sweden, 20 January 2017 - Xintela AB (publ) today announces an update of the company's projects in regenerative medicine and cancer. All projects are developing in a positive way.

New results from the cancer project show that Xintela’s targeting antibody kills glioblastoma cells both in cell studies and in an animal model.

Significant progress in the treatment of the brain tumor glioblastoma

To produce an antibody-based therapy for the brain tumor glioblastoma, Xintela has identified a suitable antibody and produced a so-called "Antibody-Drug Conjugate" (ADC), where a chemotherapy substance is linked to the antibody.

Xintela has shown that the ADC binds to tumor cells and has a cell-killing effect. Preclinical studies have been performed on both glioblastoma cells from human tumors and in an animal model of glioblastoma. The work was conducted in collaboration with researchers from the Rudbeck Laboratory at Uppsala University. Additional studies are underway to finalize results for publication in an international scientific journal.

Xintela’s goal is to identify an industrial partner at an early stage to come to market and reach patients more rapidly and generate revenues earlier.

“These positive results confirm our treatment concept and give us the data we need to initiate discussions with potential partners for further development and commercialization of a product for the treatment of glioblastoma. We can now also initiate the work of applying for an orphan drug designation for the ADC therapy,” comments Xintela’s CEO Evy Lundgren-Åkerlund.

Xintela is also analyzing tumor tissue samples to evaluate the possibility of developing a so-called Companion Diagnostic.

“Glioblastoma is a very complex disease and there is a great need to improve diagnostic methods to develop better therapies. Our goal with a Companion Diagnostic is to show that the target molecule is expressed in the tumor and thus that the patient can respond to the treatment Xintela is developing,” says Evy Lundgren-Åkerlund.

Preparing Xintela’s stem cells for clinical trials in horses and humans

Xintela previously announced that the company has successfully completed a study in horses showing Xintela’s stem cells are safe and have a protective effect on joint cartilage and bone after cartilage damage. These positive results have enabled Xintela to begin preparing for a clinical study in horses with osteoarthritis, planned to start in the second half of 2017. The study will be performed at Evidensia Equine Specialist Hospital in Helsingborg in collaboration with Casper Lindegaard, Head of Equine Surgery, who is an internationally recognized equine surgeon.

“In order to start the clinical study on horses, we need to produce stem cells under GMP (Good Manufacturing Practice) and we expect to land a cooperation agreement for production shortly. We are also preparing to commercialize the stem cell product for horses,” says Evy Lundgren-Åkerlund.

Xintela has also made great progress in developing a stem cell product for the treatment of osteoarthritis in humans. The results of the completed horse study are very important to achieve regulatory approval for clinical trials in humans.

“We have already identified an orthopedic specialist clinic where we plan to conduct the clinical trial, aiming to start the study in 2018. We are now preparing for discussions with regulatory authorities for permission to start clinical studies,” says Evy Lundgren-Åkerlund.

XACT ™ assures the quality of cartilage cells and stem cells

During the year Xintela successfully validated the analytical test XACT™ for quality assurance of cartilage cells in cooperation with a European company. The results show that XACT™, comprising antibodies binding to Xintela’s integrin markers α10β1 respectively integrin α11β1, can determine the quality of cartilage cells prior to cartilage cell implantation and can also detect contaminating cells in cartilage cell preparations. Discussions regarding further collaborations are ongoing.

“This has been a fruitful cooperation for Xintela. It has generated revenues and given us the opportunity to further develop XACT™ to meet the needs of our customers. XACT™ is a unique quality assurance test and we have collaboration discussions ongoing with several international players in the field,” says Evy Lundgren-Åkerlund.

Xintela also successfully used XACT™ to select and quality assure the stem cells used in the horse study and also to verify that the same type of stem cells can be selected from human tissues.

Many of Xintela’s milestones have already been met

Xintela has already achieved important milestones which were communicated when Xintela was listed 10 months ago.

“I am delighted that in such a short time we have been able to report positive results in our two main projects in regenerative medicine and cancer. This demonstrates the strength of our XINMARK™ technology platform and our results-focused team. I look forward to the continued development of the projects and I am confident that 2017 will be an eventful year for Xintela,” says Evy Lundgren-Åkerlund.

Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 70-329 18 71
E-mail: evy@xintela.se
Medicon Village
223 81 Lund, Sweden
www.xintela.se

Media and Investor Relations related queries should be directed to:
Mårten Svanberg, Laika Consulting
Tel: +46 70-362 70 05
E-mail: marten.svanberg@laika.se
www.laika.se

About Xintela
Xintela AB (publ) is a Swedish biomedical company active in the fields of regenerative medicine and cancer, with a focus on cartilage damage and brain tumours. The key to Xintela's business is the Company's patented marker technology, XINMARK™. Xintela's markers are specific proteins which sit as "recognition flags" on certain cell surfaces.  The markers make it possible to identify and quality assure cartilage cells and stem cells and also to select a certain type of stem cells which can develop into cartilage cells. Through this technology, Xintela can, in a unique way, quality assure stem cells for the repair of damaged cartilage. The XINMARK™-technology makes it also possible to direct antibody treatment to cells in glioblastoma brain tumours with the goal to slow down tumour growth. Xintela is listed on Nasdaq First North Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North is Erik Penser Bank AB, +46 8-463 80 00.

This information is information that Xintela AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication through the agency of the contact persons set out above on 20 January 2017, at 08:30 a.m CET.

Archive

Below you will find the collected information on Xintela’s press releases, newsletters, diary events, films, media coverage and analyses.

November 13, 2017
Xintela raises 17 million SEK in debt and equity
October 17, 2017
Keld Søndergaard has resigned from the company’s Board of Directors, citing personal reasons.
September 11, 2017
Xintela building own GMP-facility for stem cell production
July 17, 2017
Xintela recruits Liselotte Theorell as Director Product Development and Quality Management
June 22, 2017
Xintela participates in multi-million, government funded initiative to form a cell and gene therapy research center
May 22, 2017
Xintela signs Memorandum of Understanding with the leading European cell therapy company, CO.DON
May 9, 2017
Xintela: Keld Sondergaard nominated as new board member
March 21, 2017
Xintela announces today that Thomas Areschoug has been recruited to the business development team......
February 8, 2017
(In Swedish) Xintela: Insynspersoner och huvudägare avser nyttja teckningsoptioner av serie TO1
January 20, 2017
Xintela reports positive preclinical results in cancer project
January 4, 2017
Xintela´s stem cells show positive treatment effects on cartilage damage in horse study
December 22, 2016
Xintela reports positive results from completed horse study
September 12, 2016
Xintela announces that Rickard Mosell has been recruited as Head of Business Development from October 1, 2016.
August 22, 2016
Xintela today announces that it has settled a dispute and will receive 1,500,000 Swedish Crowns in compensation.
June 23, 2016
Xintela announces that Christer Betsholtz has been engaged as a scientific and strategic advisor
June 1, 2016
Xintela strengthens its organisation wih the appointment of Caroline Ehrencrona as Director Clincial Development and Regulatory Affairs
April 25, 2016
Xintela initiates a study on the treatment of cartilage damage in horses in the USA.
March 16, 2016
Xintela's press releases are currently only published in Swedish. Please contact us if you have further questions.
September 28, 2017
‍Strategic decisions that builds significant value
July 19, 2017
Focusing on Stem Cell Production and Preparations for Clinical Trials
May 16, 2017
On the 21st March 2017, Xintela reported that it was strengthening its Business Development team...
April 5, 2017
A word from the CEO
April 5, 2017
The subscription period for shares supported by warrants has started
December 29, 2016
A Year of Significant Progress
December 14, 2016
Glioblastoma—Xintela's Focus in the Cancer Arena
November 8, 2016
Starting the Autumn with an increased focus on Xintela’s commercial development
October 19, 2016
Since our listing in the Spring, the company has developed in a very positive way and we are on track with the milestones we have set.
August 11, 2016
Confidence in the future with a strong organisation
August 11, 2016
Welcome to Xintela's newsletter
February 22, 2018
Year-End Report 2017
November 23, 2017
Q3 January - September 2017
February 9, 2017

Dr. Marcus Keep comments on Xintelas glioblastoma project.

January 31, 2017

Xintelas Chairman of the board and strategic advisor Greg Batcheller, tells us more about Xintelas potential and prospects.

January 30, 2017

Dr. Lisa Fortier at Cornell University, New York is interviewed by BioStock about Xintelas positive results in horse study.

December 28, 2016

In the following video interview, Karin explains her role at Xintela and what she considers to be Xintela’s primary strengths.

December 13, 2016

See the interview with Claes Post, member of the board in Xintela. The interview is in swedish with english subtitles.

March 24, 2016

See the interview with Sven Kili, member of the board in Xintela. The interview is in English (introduction is in Swedish).

March 22, 2016

See an interview with Xintela's CEO Evy Lundgren-Åkerlund, after the listing ceremony at Nasdaq First North.

March 16, 2016

Investor presentation from Lund - Jan 27

March 15, 2016

Interview with Xintelas CEO

March 23, 2016
(Article in Swedish) Grundare av Xintela ser notering som viktig milstolpe
March 23, 2016
(Article in Swedish) Xintela covered in Life Science Sweden
March 23, 2016
(Article in Swedish) Xintela tar behandling av ledskador och cancer till First North.
February 24, 2016
(Article in Swedish) Rapidus: Xintela på väg till First North
March 17, 2016
Future financial analyses of Xintela will be published here.
Top